高用量ベクロメタゾン吸入中の喘息症例における1/2用量フルチカゾン1日2回, および1日1回投与の有用性  [in Japanese] EFFECT OF FLUTICASONE PROPIONATE AT HALF DOSE OF BECLOMETHASONE DIPROPIONATE DIVIDED TWICE DAILY AND ONCE DAILY IN ASTHMATICS INHALING BECLOMETHASONE DIPROPTONATE 800 μg DAILY OR MORE  [in Japanese]

Access this Article

Author(s)

Abstract

beclomethasone dipropionate (BDP) 800μg/day以上を使用中の喘息症例47例を対象に,BDPで4週間治療 (BDP期) した後にこれを1/2用量のfluticasone propionate (FP) 1日2回投与に変更して4週間治療し (FP2期),さらに同用量のFPの1日1回投与に変更して4週間観察して(FP1期),各治療期間の有用性を比較検討した.FP2期におけるピークフロー値(PEF,329vs. 306L/min), FEV_1(1.87vs. 1.76L),症状スコア(3.6vs. 6.0/週),β_2刺激薬使用回数(2.7vs. 4.5回/日)は,すべてBDP期に比べて有意に良好であった.FP1期とFP2期とでは,これらの評価項目に有意差は認められなかった.FPは,1日2回投与では倍量のBDPよりも高い臨床効果を有しており,1日2回投与を1回投与に変更しても,少なくとも短期的には同等の有用性が得られるものと考えられた.

We conducted a 12 weeks single-arm prospective study comparing beclomethasone dipropionate (BDP), 1/2 doses of fluticasone propionate (FP) twice daily and the same dose of FP once daily in 47 asthmatics who had been inhalinn BDP 800 mcg daily or more. Peak expiratory flow (PEF) , FEV_1, a symptom score and a frectuency of β_2 agonist were all significantly better in FP twice daily phase than BDP phase (329 vs. 306 L/min, 1.87 vs. 1.76 L, 3.6 vs. 6.0/week and 2.7 vs. 4.5 puffs/day, respectively). There was no significant difference in these endpoints between FP twice daily phase and FP once daily phase. FP twice daily produced better plumonary function and symptom releif than the double doses of BDP. Furthermore, FP twice daily could, at least in a short-term basis, safely be changed into the same doses of FP once daily.

Journal

  • Japanese Journal of Allergology

    Japanese Journal of Allergology 50(4), 379-384, 2001

    Japanese Society of Allergology

References:  11

Codes

  • NII Article ID (NAID)
    110002427031
  • NII NACSIS-CAT ID (NCID)
    AN00012583
  • Text Lang
    JPN
  • Article Type
    ART
  • ISSN
    0021-4884
  • NDL Article ID
    026086467
  • NDL Call No.
    Z19-32
  • Data Source
    CJP  NDL  NII-ELS  J-STAGE 
Page Top